Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration.
Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood-brain barrier and blood-cerebrospinal fluid barrier.
Preserved vascular integrity and enhanced survival following neuropilin-1 inhibition in a mouse model of CD8 T cell-initiated CNS vascular permeability.
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.
Inhibition of autoimmune encephalomyelitis by a tetracycline.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Natural, innate improvements in multiple sclerosis disability.
Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.
Targeting the shift from m1 to m2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil.
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation.
Multiple sclerosis: An old drug plays a new trick.
Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy.
Multiple sclerosis reactivation postfingolimod cessation: Is it IRIS?
Can we safely target the WNT pathway?
Intrauterine environment and multiple sclerosis: a population- based case-control study.
Neuroaxonal regeneration is more pronounced in early multiple sclerosis than in traumatic brain injury lesions.
Biogen Idec and Elan submit applications for first-line use of Tysabri in anti-JCV antibody negative patients with MS
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis.
Evidence that nuclear factor IA inhibits repair after white matter injury.
The Afferent Visual Pathway: Designing a Structural-Functional Paradigm of Multiple Sclerosis.
Do not treat from CIS onset: evaluate disease course and prognosis first - No (treat!).

Pages